Glucose-6-Phosphate Dehydrogenase Deficiency is Associated with Cardiovascular Disease in U.S. Military Centers
- PMID: 30072850
- PMCID: PMC6059509
- DOI: 10.14503/THIJ-16-6052
Glucose-6-Phosphate Dehydrogenase Deficiency is Associated with Cardiovascular Disease in U.S. Military Centers
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) protects erythrocytes from oxidative stress and hemolysis; G6PD deficiency is the most prevalent enzymopathy. The United States military routinely performs tests to prevent exposing G6PD-deficient personnel to antimalarial drugs that might cause life-threatening hemolytic reactions. In addition, G6PD is a key determinant of vascular function, and its deficiency can lead to impaired nitric oxide production and greater vascular oxidant stress-precursors to atherosclerosis and cardiovascular disease. Using military medical records, we performed a retrospective, cross-sectional study to investigate whether deficient G6PD levels are associated with a higher prevalence of cardiovascular disease than are normal levels, and, if so, whether the relationship is independent of accepted cardiovascular risk factors. We analyzed the medical records of 737 individuals who had deficient G6PD levels and 16,601 who had normal levels. Everyone had been screened at U.S. military medical centers from August 2004 through December 2007. We evaluated our dependent variable (composite cardiovascular disease) at the individual level, and performed binary logistic regression of our independent variable (G6PD status) and control variables (modifiable cardiovascular risk factors). The adjusted odds ratio of 1.396 (95% CI, 1.044-1.867; P <0.05) indicated that G6PD-deficient individuals have 39.6% greater odds of developing cardiovascular disease than do those with normal levels. Early intervention may reduce the incidence of cardiovascular disease in military personnel and civilians who have deficient G6DP levels.
Keywords: Cardiovascular diseases/ethnology/enzymology/physiopathology; United States/epidemiology; delivery of health care; genetic predisposition to disease; glucose phosphate dehydrogenase deficiency/analysis/complications/diagnosis/epidemiology; mass screening; military medicine; retrospective studies; risk assessment; risk factors.
Figures
![Fig. 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf20/6059509/88b1804a9fd4/i1526-6702-45-3-144-f01.gif)
Similar articles
-
Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel.Mil Med. 2006 Sep;171(9):905-7. doi: 10.7205/milmed.171.9.905. Mil Med. 2006. PMID: 17036616
-
Glucose-6-phosphate dehydrogenase deficiency in Tunisian jaundiced neonates.Ann Biol Clin (Paris). 2020 Aug 1;78(4):411-416. doi: 10.1684/abc.2020.1558. Ann Biol Clin (Paris). 2020. PMID: 32576539
-
Heterogeneity of G6PD deficiency prevalence in Mozambique: a school-based cross-sectional survey in three different regions.Malar J. 2017 Jan 19;16(1):36. doi: 10.1186/s12936-016-1674-y. Malar J. 2017. PMID: 28103889 Free PMC article.
-
Should blood donors be routinely screened for glucose-6-phosphate dehydrogenase deficiency? A systematic review of clinical studies focusing on patients transfused with glucose-6-phosphate dehydrogenase-deficient red cells.Transfus Med Rev. 2014 Jan;28(1):7-17. doi: 10.1016/j.tmrv.2013.10.003. Epub 2013 Oct 30. Transfus Med Rev. 2014. PMID: 24289973 Review.
-
G6PD deficiency: its role in the high prevalence of hypertension and diabetes mellitus.Ethn Dis. 2001 Fall;11(4):749-54. Ethn Dis. 2001. PMID: 11763298 Review.
Cited by
-
Glucose-6-Phosphate Dehydrogenase Deficiency Activates Endothelial Cell and Leukocyte Adhesion Mediated via the TGFβ/NADPH Oxidases/ROS Signaling Pathway.Int J Mol Sci. 2020 Oct 10;21(20):7474. doi: 10.3390/ijms21207474. Int J Mol Sci. 2020. PMID: 33050491 Free PMC article.
-
The pentose phosphate pathway in health and disease.Nat Metab. 2023 Aug;5(8):1275-1289. doi: 10.1038/s42255-023-00863-2. Epub 2023 Aug 23. Nat Metab. 2023. PMID: 37612403 Free PMC article. Review.
-
Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.Malar J. 2022 Sep 8;21(1):260. doi: 10.1186/s12936-022-04269-5. Malar J. 2022. PMID: 36076204 Free PMC article.
-
Hematologic and systemic metabolic alterations due to Mediterranean class II G6PD deficiency in mice.JCI Insight. 2021 Jul 22;6(14):e147056. doi: 10.1172/jci.insight.147056. JCI Insight. 2021. PMID: 34138756 Free PMC article.
-
Mediterranean G6PD variant rats are protected from Angiotensin II-induced hypertension and kidney damage, but not from inflammation and arterial stiffness.Vascul Pharmacol. 2022 Aug;145:107002. doi: 10.1016/j.vph.2022.107002. Epub 2022 May 24. Vascul Pharmacol. 2022. PMID: 35623546 Free PMC article.
References
-
- Luzzatto L, Poggi V. Glucose-6-phosphate dehydrogenase deficiency. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, editors. Nathan and Oski's hematology of infancy and childhood. 7th ed. Vol. 1. Philadelphia: Saunders Elsevier; 2009. pp. 883–907. p.
-
- Benjamin IJ, Arnett DK, Loscalzo J, American Heart Association Basic Science Writing Group Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Basic Science Writing Group. Circulation. 2005;111(10):e120–3. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous